We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Severe acute respiratory syndrome coronavirus 2 spike antibody level decline is more pronounced after the second vaccination, but response to the third vaccination is similar in people with type 1 and type 2 diabetes compared with healthy controls: The prospective COVAC‐DM cohort study
- Authors
Sourij, Caren; Aziz, Faisal; Kojzar, Harald; Obermayer, Anna M.; Sternad, Christoph; Müller, Alexander; Tripolt, Norbert J.; Pferschy, Peter N.; Aberer, Felix; Schlenke, Peter; Kleinhappl, Barbara; Stradner, Martin; Sareban, Nazanin; Moritz, Martina; Dominguez‐Villar, Margarita; Oliver, Nick; Steinmetz, Ivo; Sourij, Harald
- Abstract
Keywords: COVID-19; type 1 diabetes; type 2 diabetes; vaccination EN COVID-19 type 1 diabetes type 2 diabetes vaccination 314 318 5 12/13/22 20230101 NES 230101 CONTEXT Up to 1 June 2022, almost 12 billion vaccine doses for coronavirus disease 2019 (COVID-19) were administered worldwide.[1] People with diabetes were more probable to be hospitalized for COVID-19 and were observed to have in-hospital mortality as high as 25%.[[2]] Hence COVID-19 vaccination is not only recommended with priority in people with diabetes, it has also been shown to be effective in people with diabetes.[[4]] Our research group previously showed that humoral immune response 2-3 weeks after the second COVID-19 vaccination is similar in people with type 1 diabetes, type 2 diabetes and healthy controls,[6] irrespective of glycaemic control. The prospective COVAC-DM cohort study However, the decline of the antibody levels after the vaccination appears to be more pronounced in people with diabetes irrespective of glycaemic control, suggesting that shorter vaccination intervals may be necessary in both people with type 1 and type 2 diabetes, with the latter group showing the lowest antibody levels 6 months after the second vaccination. GLO:EU1/01jan23:dom14855-fig-0001.jpg PHOTO (COLOR): 1 A, Median anti-severe acute respiratory syndrome coronavirus 2 spike protein (SARS-CoV-2S) antibody titres post-second vaccination and pre-third vaccination in healthy controls, type 1 diabetes and type 2 diabetes.
- Subjects
SARS-CoV-2; TYPE 1 diabetes; IMMUNOGLOBULINS; TYPE 2 diabetes; VACCINATION; MEDICAL ethics
- Publication
Diabetes, Obesity & Metabolism, 2023, Vol 25, Issue 1, p314
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.14855